Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance.
J. E. Chaft
No relevant relationships to disclose
G. R. Oxnard
No relevant relationships to disclose
V. A. Miller
Consultant or Advisory Role - ArQule; Boehringer Ingelheim; Genentech; Pfizer; Roche
Honoraria - ArQule; Boehringer Ingelheim; Genentech; Pfizer; Roche
Research Funding - Boehringer Ingelheim; Genentech; Pfizer
M. G. Kris
Consultant or Advisory Role - Boehringer Ingelheim; Pfizer
C. S. Sima
No relevant relationships to disclose
G. J. Riely
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim